The Business Case For Health Economics And Outcomes Research With ISPOR's Rob Abbott

We love to hear from our listeners. Send us a message. (buzzsprout.com/1011661/fan_mail/new)
On this week's episode of the Business of Biotech, Rob Abbott, CEO of ISPOR, explains how startup and early-stage clinical drug development companies benefit from conducting health economics and outcomes research (HEOR), and not just with patients and commercial payers. HEOR, viewed as a strategic lever as opposed to a compliance exercise, can help answer investor questions about market differentiation, pricing pathways, and real world product validation. Abbott talks about the value of cost-of-illness studies, burden-of-disease analyses, and payer landscape assessments, and how AI, real world evidence, and patient-centered research can improve drug and trial design and accelerate market access.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (lifescienceleader.com/solution/the-business-of…) tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter (www9.lifescienceleader.com/business-of-biotech…).

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: linkedin.com/in/bencomer